AI Article Synopsis

  • Study aimed to identify factors that predict the risk of head and neck lymphedema (HNL) after radiation therapy for head and neck cancer (HNC) due to its impact on patient quality of life.
  • Researchers analyzed data from 76 patients who underwent radiation therapy, focusing on clinical, disease-related, and dosimetric factors to develop predictive models for both external and internal HNL.
  • Key findings revealed that lymph node status, specifically the number of lymph nodes removed and advanced adenopathy, were significant predictors for external lymphedema, while advanced adenopathy and specific radiation doses to the larynx were associated with internal lymphedema risk.

Article Abstract

Purpose: Head and neck lymphedema (HNL) following radiation therapy for head and neck cancer (HNC) causes patient morbidity. Predicting individual patients' risk of HNL after treatment is challenging. We aimed to identify the demographic, disease-related, and treatment-related factors associated with external and internal HNL following treatment of HNC with definitive or adjuvant radiation therapy.

Methods And Materials: Relevant clinical, pathologic, and dosimetric data for 76 consecutive patients who received definitive or adjuvant radiation ± chemotherapy were retrospectively collected from a single institution. Multivariable models predictive of external and internal lymphedema using clinicopathologic variables alone and in combination with dosimetric variables were constructed and optimized using competing risk regression.

Results: After median follow-up of 550 days, the incidence of external and internal HNL at 360 days was 70% and 34%, respectively. When evaluating clinical and treatment-related factors alone, number of lymph nodes removed and advanced adenopathy status were predictive of external lymphedema. With incorporation of dosimetric variables, the optimized model included the percentage volume of the contralateral lymph node level VII receiving 30Gy V30 ≥50%, number of lymph nodes removed, and advanced adenopathy status. For internal lymphedema, our clinicopathologic model identified both adjuvant radiation, as opposed to definitive radiation, and advanced adenopathy status. With inclusion of a dosimetric variable, the optimized model included larynx V45 ≥50% and advanced adenopathy.

Conclusions: HNL following HNC treatment is common. For both external and internal lymphedema, nodal disease burden at diagnosis predicts increased risk. For external lymphedema, increasing extent of lymph node dissection prior to adjuvant therapy increases risk. The contralateral level VII lymph node region is also predictive of external lymphedema when radiation dose to V30 is ≥50%, meriting investigation. For internal lymphedema, we confirm that increasing radiation dose to the larynx is the most significant dosimetric predictor of mucosal edema when larynx V45 is ≥50%.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11343725PMC
http://dx.doi.org/10.1016/j.adro.2024.101545DOI Listing

Publication Analysis

Top Keywords

head neck
16
adjuvant radiation
16
external internal
16
internal lymphedema
16
definitive adjuvant
12
predictive external
12
advanced adenopathy
12
adenopathy status
12
external lymphedema
12
lymph node
12

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!